Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients

Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Are at least 13 years old (need consent of parent or guardian if under 18). * Have an HIV count of 5,000 copies/ml or more within 30 days prior to study entry. * Have a CD4+ count of 50 cells/mm3 or more. Exclusion Criteria You will not be eligible for this study if you: * Are diagnosed with hepatitis within 30 days prior to study entry. * Have certain serious medical conditions, including an AIDS-defining clinical condition. * Received chemotherapy or radiation therapy within 30 days of study entry. * Have taken any nucleoside reverse transcriptase inhibitors (NRTIs) for more than 2 weeks. * Have ever taken 3TC. * Have ever taken any non-nucleoside reverse transcriptase inhibitors (NNRTIs). * Have taken medications that affect your immune system within 30 days prior to study entry. * Have received a vaccine within 30 days prior to study entry. * Are enrolled in another anti-HIV drug study while participating in this study. * Abuse alcohol or drugs. * Are pregnant or breast-feeding.